A study published in the New England Journal of Medicine represents the first clinical trial to test whether doxycycline postexposure prophylaxis (PEP) would prevent sexually transmitted infections (STIs) among cisgender women. Researchers considered 224 subjects assigned to a doxycycline-PEP group and 225 to a standard-care group over 12 months. A total of 109 incident STIs occurred: 50 in the doxycycline-PEP group and 59 in the standard-care group. Chlamydia accounted for 85 of the STIs (78%) with 35 …
Read More